Galimedix, Inc. | WebDisclosure

Basculer en Français

10678	Companies
227845	Keywords
156276	Articles
120730	Press releases

Home
Companies
Galimedix, Inc.

PRESS RELEASE

published on 05/06/2025 at 14:00, 1 year 1 month ago

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Galimedix Therapeutics completes single ascending dose of Phase 1 study with oral small molecule GAL-101 targeting amyloid beta aggregation modulator, supporting oral administration route. Next study arms and indications revealed

Galimedix Therapeutics GAL-101 Oral Administration Phase 1 Study Amyloid Beta
BRIEF

published on 04/01/2025 at 09:05, 1 year 3 months ago

Galimedix Reports Promising Data for Alzheimer's Treatment

Alzheimer's Disease GAL-201 Galimedix Therapeutics Neuroinflammation Amyloid-β Aggregation
BRIEF

published on 04/01/2025 at 09:05, 1 year 3 months ago

Galimedix publie des données prometteuses pour le traitement de la maladie d'Alzheimer

GAL-201 Maladie D'Alzheimer Galimedix Therapeutics Neuroinflammation Agrégation De L'amyloïde-β
PRESS RELEASE

published on 04/01/2025 at 09:00, 1 year 3 months ago

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomod
Galimedix Therapeutics presents new preclinical data on GAL-201 at AD/PD 2025, showing promise in Alzheimer’s disease treatment by targeting misfolded Aβ monomers and reducing Aβ plaques with anti-inflammatory effects

Alzheimer's Disease Preclinical Data GAL-201 Galimedix Therapeutics Neuroinflammation
BRIEF

published on 03/24/2025 at 15:12, 1 year 3 months ago

Galimedix Therapeutics présente un traitement préclinique prometteur contre la maladie d'Alzheimer

Galimedix Therapeutics Neuroprotection Données Précliniques Traitement De La Maladie D'Alzheimer Bêta-amyloïde
BRIEF

published on 03/24/2025 at 15:12, 1 year 3 months ago

Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment

Preclinical Data Galimedix Therapeutics Neuroprotection Alzheimer's Treatment Amyloid-beta
PRESS RELEASE

published on 03/24/2025 at 15:07, 1 year 3 months ago

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference

Alzheimer's Disease Galimedix Therapeutics Pre-clinical Data AD/PD 2025 Conference Aβ Aggregation Modulator
BRIEF

published on 12/23/2024 at 17:35, 1 year 6 months ago

Galimedix débute un essai de phase 2 avec les gouttes ophtalmiques GAL-101 pour la DMLA sèche

Étude De Phase 2 Neuroprotection GAL-101 DMLA Sèche Atrophie Géographique
BRIEF

published on 12/23/2024 at 17:35, 1 year 6 months ago

Galimedix Begins Phase 2 Trial with GAL-101 Eye Drops for Dry AMD

Phase 2 Study Neuroprotection GAL-101 Dry AMD Geographic Atrophy
PRESS RELEASE

published on 12/23/2024 at 17:30, 1 year 6 months ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy

Accesswire

Published on 07/03/2026 at 00:45, 6 hours 30 minutes ago

FireFox Gold Finalizes Finders Fees on Recent Offering
Published on 07/03/2026 at 00:05, 7 hours 10 minutes ago

Update to Tintina Mines Previous Announcement on June 2, 2026 of a C$91 Million Private Placement and Strategic Partnership with the Gignac Family and Sumitomo Corporation for the Development of the Domeyko Sulfuros Copper-Gold Project in Chile
Published on 07/03/2026 at 00:00, 7 hours 15 minutes ago

Redwood AI Added to CSE25 Index as One of the Largest Companies Listed on the Canadian Securities Exchange
Published on 07/02/2026 at 23:05, 8 hours 10 minutes ago

AI/ML Innovations Announces Completion of Share Issuance
Published on 07/02/2026 at 19:45, 11 hours 30 minutes ago

Infield Minerals Issues Shares for Kings Canyon Gold Property Option Payment

View all ACCESSWIRE

EQS Group

Published on 07/03/2026 at 07:00, 15 minutes ago

Julius Baer appoints Peter Burrill as Chief Financial Officer and Member of Executive Board
Published on 07/03/2026 at 07:00, 15 minutes ago

THINKCAR dévoile Tyler, le premier agent de diagnostic IA du secteur, lors de sa Conférence mondiale des distributeurs
Published on 07/03/2026 at 07:00, 15 minutes ago

THINKCAR Unveils Tyler as the Industry's First AI Diagnostic Agent at Global Distributors Conference
Published on 07/03/2026 at 07:00, 15 minutes ago

Further rating upgrade: S&P Global raises TAG’s rating to “BBB” following Moody’s upgrade to “Baa2” in May
Published on 07/03/2026 at 06:45, 30 minutes ago

Taux de réussite de 100% aux examens de fin d’apprentissage chez mobilezone

Les Echos

Published on 07/02/2026 at 18:33, 12 hours 42 minutes ago

Annonce des principales caractéristiques d'un projet d'offre publique de retrait et désignation expert financier
Published on 07/02/2026 at 18:28, 12 hours 47 minutes ago

Emova Group - Résultats 1er semestre 2025/26
Published on 07/02/2026 at 18:00, 13 hours 15 minutes ago

Publication du nombre d’actions composant le capital et du nombre total de droits de vote au 30 juin 2026
Published on 07/02/2026 at 18:00, 13 hours 15 minutes ago

Outstanding shares and voting rights statement at 30 June 2026
Published on 07/02/2026 at 17:45, 13 hours 30 minutes ago

ENGIE va construire plus de 400 km de nouvelles lignes de transmission électrique au Pérou

View all LES ECHOS COMFI WIRE